NewsRoom Articles - Page 85 of 154 - PsychedelicNewsWire (PNW)

TuesdaySep 14, 2021 12:35 pm

Michigan Senators Introduce Bill to Legalize Cultivation, Possession of Psychedelic Substances

Last week, senators in the state of Michigan introduced a piece of legislation that would legalize the possession, growing and delivery of various fungi- and plant-derived psychedelics, including mescaline and psilocybin. The bill, which was sponsored by Senators Adam Hollier and Jeff Arwin, would alter state statutes to exempt individuals from criminal penalties for such activities, as long as they weren’t receiving valuable consideration, cash as money for the entheogenic fungi and/or plants. This is because commercial sales and production of the psychedelics wouldn’t be legal under the initiative. However, the measure does clarify that individuals would be allowed to…

TuesdaySep 14, 2021 9:48 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Likely to Benefit from New Research Touting Psilocybin Mental Health Treatments

Yale researchers publish study that a single dose of psilocybin counteracts symptoms of depression Administering drug to mice resulted in an approximately 10% increase in neuron size and density Cybin is focused on progressing psychedelic therapeutics As news of psychedelic research continues to report breakthroughs — such as the recent news from a group of Yale researchers that a single dose of psilocybin counteracts symptoms of depression (https://ibn.fm/NCORl) — companies operating in the space, including Cybin (NEO: CYBN) (NYSE American: CYBN), are ideally positioned to see significant benefits and growth. “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin…

MondaySep 13, 2021 2:07 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook

So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics space The company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disorders Tryp has also been keen on collaborating and partnering with key players in the industry, such as Calvert Labs and Gad Consulting services, the University of Michigan, and the University of Florida The company also understands the value of proper leadership and, so far in 2021, it has made strategic appointments to its board of directors Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF)…

MondaySep 13, 2021 12:35 pm

Biden Administration Streamlines Registration Processes for Research on Schedule I Substances

Last week, the White House Office of National Drug Control Policy recommended that a modification be made to the federal drug scheduling system in an effort to simplify the process of conducting studies on schedule I substances, which include cannabis and psychedelics like psilocybin. In a letter to Congressional leaders, the ONDCP stated that it wanted to encourage research on the substances by streamlining the registration process for researchers to access Schedule I drugs. This move is part of an extensive initiative to develop a strategy to decrease the supply of illicit fentanyl while diminishing barriers to scientific research on…

FridaySep 10, 2021 2:00 pm

DEA to Increase Psilocybin, Cannabis Production for Research Purposes

The United States Drug Enforcement Administration (“DEA”) has proposed an increase in the manufacture of cannabis, cannabis extract, psilocin and psilocybin for clinical trial and research purposes. In its most recent notice, the DEA stated that its objective was to assist in the development of new federally approved therapies. The DEA stated that it believes in supporting the regulated research of controlled substances classified under Schedule I of the Controlled Substances Act. The increase in the aggregate production quota reflects this support and will help meet the requirements for research needed for the production of new therapeutic medications. This isn’t…

ThursdaySep 09, 2021 1:45 pm

Study Finds That Ayahuasca May Enhance Self-Perception of Patients with Social Anxiety Disorder

A study that was recently published in the “Journal of Clinical Psychopharmacology” has found that ayahuasca could enhance the self-perception of individuals with social anxiety disorder. Ayahuasca is a psychedelic brew that has been used for hundreds of years by indigenous tribes in the Amazon. It contains monoamine oxidase inhibitors and DMT (dimethyltryptamine), another potent psychedelic. Preliminary studies have provided evidence suggesting that ayahuasca is psychologically beneficial to individuals who suffer from depression and anxiety. Rafael Guimarães dos Santos, the study’s author, states that social anxiety disorder is an under-diagnosed and prevalent disorder with limited treatment options. In the study,…

ThursdaySep 09, 2021 11:24 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference

Tryp Therapeutics is set to present at the H.C Wainwright 23rd Annual Global Investor Conference scheduled for Sept. 13-15, 2021 Greg McKee, company chairman and CEO, will provide an overview of the business and its pipeline, including the Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program Tryp’s presentation will be available on-demand from 7.00 a.m. EDT on Sept. 13 Through the PFN program, Tryp is focused on developing psychedelic compounds targeting diseases with high unmet medical needs, such as chronic pain conditions and eating disorders As a company at the forefront of the psychedelic renaissance, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has differentiated itself…

WednesdaySep 08, 2021 1:30 pm

Newfoundland Women Report Using Psychedelics Medicinally and Hope for Legalization

Researchers have found that psilocybin, which is the hallucinogenic compound found in so-called magic mushrooms, has shown potential in treating various mental conditions, including anxiety, major depressive disorder and addiction. A woman in Newfoundland who was diagnosed with severe PTSD revealed that psilocybin helped get her life back. The woman, whose identity remains withheld, stated that after her diagnosis, conventional medications and therapies helped for a while, but she eventually became resistant to them. When her sleep and anxiety became worse, she went to a psilocybin psychotherapy retreat in Jamaica where the substance is legal. She gave an account of…

WednesdaySep 08, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders

Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapy Tryp recently announced that its educational partner, Fluence, has completed training of the psychotherapists who will be involved in administering the drug candidate to help establish minimal variability in the data outcomes and grant the patients the best possible…

TuesdaySep 07, 2021 2:00 pm

Not-for-Profit Organization Urges Health Canada to End Psilocybin Mushroom Prohibition

TheraPsil is urging Health Canada to end the five-decade prohibition against the possession of psilocybin mushrooms and the psychedelics these entheogenic fungi produce. The not-for-profit organization, which advocates for the therapeutic use of psilocybin, has spent months drawing up proposed legalization measures for these mushrooms based on the same regulations the federal government created for medical marijuana two decades ago. Spencer Hawkswell, CEO of the British, Columbia-based organization stated that TheraPsil had sent a proposal to Jennifer Saxe, who is the director general of Health Canada. In his statement, Hawkswell revealed that the 165-page document focused on managing every aspect…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000